4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 6.2% – Should You Buy?
by Sarita Garza · The Markets Daily4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report)’s stock price rose 6.2% during trading on Monday . The company traded as high as $9.54 and last traded at $9.58. Approximately 278,901 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 751,524 shares. The stock had previously closed at $9.02.
Wall Street Analyst Weigh In
FDMT has been the subject of a number of recent research reports. Royal Bank Of Canada reissued an “outperform” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Leerink Partners reiterated an “outperform” rating and set a $17.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, Chardan Capital restated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, December 18th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.25.
Get Our Latest Research Report on FDMT
4D Molecular Therapeutics Price Performance
The company has a fifty day moving average price of $8.43 and a 200 day moving average price of $8.86. The company has a market cap of $566.73 million, a PE ratio of -2.65 and a beta of 3.01.
Institutional Trading of 4D Molecular Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd purchased a new stake in 4D Molecular Therapeutics during the 1st quarter valued at $39,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. Los Angeles Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at approximately $42,000. Quadrature Capital Ltd purchased a new stake in shares of 4D Molecular Therapeutics in the second quarter worth $42,000. Finally, Farther Finance Advisors LLC raised its holdings in 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.